SGK1: a novel prognostic marker and potential drug target in medulloblastoma

被引：0
|
作者：
Pleier, S. [1 ,2 ]
Sturm, D. [1 ]
Remke, M. [1 ,2 ]
Witt, H. [1 ,2 ]
Goidts, V [1 ,2 ]
Reifenberger, G. [3 ]
Felsberg, J. [3 ]
Kulozik, A. E. [2 ]
Korshunov, A. [4 ]
Lichter, P. [1 ]
Pfister, S. M. [1 ,2 ]
机构：
[1] German Canc Res Ctr Heidelberg, Div Mol Genet, Heidelberg, Germany
[2] Univ Heidelberg Hosp, Dept Pediat Oncol Hematol & Immunol, Heidelberg, Germany
[3] Univ Dusseldorf, Dept Neuropathol, D-4000 Dusseldorf, Germany
[4] Univ Heidelberg Hosp, Dept Neuropathol, Heidelberg, Germany
来源：
KLINISCHE PADIATRIE | 2011年 / 223卷 / 03期
关键词：
D O I：
10.1055/s-0031-1277081
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
20
引用
收藏
页码：197 / 198
页数：2
相关论文
共 50 条
  • [31] Serum and glucocorticoid-regulated kinase 1 (SGK1) as an emerging therapeutic target for cardiac diseases
    Yarmohammadi, Fatemeh
    Karimi, Gholamreza
    PHARMACOLOGICAL RESEARCH, 2024, 208
  • [32] PSMD1 as a prognostic marker and potential target in oropharyngeal cancer
    Park, Hae Chan
    Kim, Hyojin
    Kim, Ji-Yeong
    Lee, Hye-Yeon
    Lee, Jinyi
    Cha, WonJae
    Ahn, Soon-Hyun
    Jeong, Woo-Jin
    BMC CANCER, 2023, 23 (01)
  • [33] PSMD1 as a prognostic marker and potential target in oropharyngeal cancer
    Hae Chan Park
    Hyojin Kim
    Ji-Yeong Kim
    Hye-Yeon Lee
    Jinyi Lee
    WonJae Cha
    Soon-Hyun Ahn
    Woo-Jin Jeong
    BMC Cancer, 23
  • [34] The novel YAP target gene, SGK1, upregulates TAZ activity by blocking GSK3β-mediated TAZ destabilization
    Yoo, Geon
    Kim, Tackhoon
    Chung, Chaeuk
    Hwang, Deog-Su
    Lim, Dae-Sik
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 490 (03) : 650 - 656
  • [35] Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma
    Prince, Eric W.
    Balakrishnan, Ilango
    Shah, Monil
    Levy, Jean M. Mulcahy
    Griesinger, Andrea M.
    Alimova, Irina
    Harris, Peter S.
    Birks, Diane K.
    Donson, Andrew M.
    Davidson, Nathan
    Remke, Marc
    Taylor, Michael D.
    Handler, Michael H.
    Foreman, Nicholas K.
    Venkataraman, Sujatha
    Vibhakar, Rajeev
    ONCOTARGET, 2016, 7 (33) : 53881 - 53894
  • [36] SGK1 inhibition attenuates the action potential duration in reengineered heart cell models of drug-induced QT prolongation
    Kim, Maengjo
    Sager, Philip T.
    Tester, David J.
    Pradhananga, Sabindra
    Hamrick, Samantha K.
    Srinivasan, Dinesh
    Das, Saumya
    Ackerman, Michael J.
    HEART RHYTHM, 2023, 20 (04) : 589 - 595
  • [37] CHECKPOINT KINASE 1 EXPRESSION IS AN ADVERSE PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN MYC-DRIVEN MEDULLOBLASTOMA
    Prince, Eric
    Shah, Monil
    Venkataraman, Sujatha
    Balakrishnan, Ilango
    Alimova, Irina
    Harris, Peter
    Birks, Diane
    Donson, Andrew
    Taylor, Michael
    Handler, Michael
    Foreman, Nicholas
    Vibhakar, Rajeev
    NEURO-ONCOLOGY, 2015, 17 : 24 - 24
  • [38] SGK1 protein expression is a prognostic factor of lung adenocarcinoma that regulates cell proliferation and survival
    Pan, Hui
    Lv, Wang
    Li, Zhoubin
    Han, Weili
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2019, 12 (02): : 391 - 408
  • [39] Diverse Effects of ANXA7 and p53 on LNCaP Prostate Cancer Cells Are Associated with Regulation of SGK1 Transcription and Phosphorylation of the SGK1 Target FOXO3A
    Srivastava, Meera
    Leighton, Ximena
    Starr, Joshua
    Eidelman, Ofer
    Pollard, Harvey B.
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [40] SGK1, a potential regulator of c-fms related breast cancer aggressiveness
    Jacob Tangir
    Nathalie Bonafé
    Maureen Gilmore-Hebert
    Octavian Henegariu
    Setsuko K. Chambers
    Clinical & Experimental Metastasis, 2004, 21 : 477 - 483
12345